汇丰大幅调升复星医药目标价 52.2% 理由是什么？

Zhitong
2021.07.16 02:30
智通财经 APP 获悉，汇丰研究发布研究报告，复星医药 (02196) 多款新药可带动收入增长，同时疫苗、CAR-T 细胞治疗、医美项目可进一步带动增长，维持 “买入” 评级，目标价由 46 港元大幅调升 52.2% 至 70 港元。
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.